Our Vision
We aim to empower patients for better healthcare with Artificial Intelligence.
AI in Healthcare is Our Passion
We develop advanced medical devices powered with Artificial Intelligence.
Solutions to Real Problems
We employ Artificial Intelligence for objective and clinically relevant analysis of medical images.
From Lund to New York
We are partnered with a global leader in theranostic medicine to target and treat cancer.
News!
News!
Syntermed appointed by Lantheus as
distributor of PYLARIFY AI™
distributor of PYLARIFY AI™
Syntermed announces its appointment by Lantheus Holdings, Inc. as the first U.S. distributor of PYLARIFY AI™, the first and only FDA-cleared artificial intelligence platform developed to assist standardized quantification of PSMA PET/CT scans.
Based in Atlanta, GA, since 1999, Syntermed, Inc. is a worldwide global imaging and informatics company supporting the clinical quantification of SPECT/PET cardiology and neuroradiology studies.
“We have a 20+ year history of collaborating with industry thought leaders to deliver innovative healthcare software solutions focused on improving clinical efficiency and patient outcomes,” said Michael Lee, CEO of Syntermed. “The opportunity to work with an industry leader such as Lantheus to enhance the integration of PSMA PET/CT into clinical practice by offering PYLARIFY AI™ aligns perfectly with Syntermed’s mission and expertise.”
Read More“We have a 20+ year history of collaborating with industry thought leaders to deliver innovative healthcare software solutions focused on improving clinical efficiency and patient outcomes,” said Michael Lee, CEO of Syntermed. “The opportunity to work with an industry leader such as Lantheus to enhance the integration of PSMA PET/CT into clinical practice by offering PYLARIFY AI™ aligns perfectly with Syntermed’s mission and expertise.”
EXINI received FDA clearance for
aPROMISE in the United States
aPROMISE in the United States
On July 27th, EXINI Diagnostics AB, was granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its digital application, aPROMISE™. aPROMISE was developed to quantify and standardize assessments of PSMA PET/CT images and will support the use of PYLARIFY® (piflufolastat F 18) in the U.S. aPROMISE is a convenient software platform that offers quantitative analysis and standardized reporting of PSMA PET/CT image assessments.
“With FDA clearance of aPROMISE, EXINI continues on the path to improve clinical management of prostate cancer patients with innovative and clinically relevant imaging biomarkers.” Aseem Anand, Vice President and Site Manager of EXINI Diagnostics AB, Sweden.
Read More“With FDA clearance of aPROMISE, EXINI continues on the path to improve clinical management of prostate cancer patients with innovative and clinically relevant imaging biomarkers.” Aseem Anand, Vice President and Site Manager of EXINI Diagnostics AB, Sweden.
aBSI is now available in United Kingdom
The EXINI devices, aBSI and EXINI bone, are now available in the United Kingdom again. EXINI Diagnostics has performed the necessary actions to be able to provide the devices to the UK customers after Brexit. QAdvis UK Ltd has been appointed as responsible person (UKRP) in the UK. Thereby we are able to continue to provide our innovative CE marked devices aBSI and EXINI bone to our UK customers.
Read MoreEXINI Diagnostics AB has
achieved MDR-certification
achieved MDR-certification
The new European Medical Device Regulation 2017/745 (MDR) which replaces the Medical Devices Directive (93/42/EEC) will be mandatory from May 25th 2021. EXINI Diagnostics has through hard work and dedication received our MDR-certificate through our Notified Body TÜV SÜD.
“We are proud to be certified for MDR and look forward to enhancing the care of cancer patients with digital AI-solutions”
Dr. Aseem Anand. Vice President EXINI Diagnostics AB.
Read More“We are proud to be certified for MDR and look forward to enhancing the care of cancer patients with digital AI-solutions”
Dr. Aseem Anand. Vice President EXINI Diagnostics AB.
Previous
Next
aBSI
Read about our automatic bone scan index software.
aPROMISE
Find out more about our latest product available for oncology.
Find Us at the Top of Lund
Get in contact with us.
EXINI
Find out more about EXINI and what we do.
What do the experts say about the future of AI in medical imaging?
Providing a quantifiable and reproducible assessment of PSMA uptake and distribution in the body is critical here to enable precision oncology in prostate cancer.
Andrew J. Armstrong, MD.
Divisions of Medical Urology and Oncology, Duke University, NC, USA
The quantification and standardization of PSMA scan reports is a major step forward to enhance the reproducibility and timeliness of scan interpretations.
Matthew B. Rettig, MD.
Professor of medicine and urology, David Geffen School of Medicine at UCLA, CA, USA
Modern chess AI running on even modest hardware can easily defeat the greatest human grand masters. There’s no reason to think the eventual outcome will be any different with diagnostic imaging. PSMA-AI is a step towards that goal.
Stephan Probst
Chief of Nuclear Medicine, Jewish General Hospital, MontrÉal, Canada.
Artificial intelligence is essential to advance molecular imaging in cancer, to capture the power of MI for detection and quantitating molecular expression of individual tumor lesions within the prostate cancer patient.
Steven M. Larson, MD.
Department of Radiology, Memorial Sloan Kettering Cancer Center, NY, USA